Comparison of Acute Transient Dyspnea after Intravenous Administration of Gadoxetate Disodium and Gadobenate Dimeglumine: Effect on Arterial Phase Image Quality

• DOI: 10.1148/radiol.12120826
• Publication Date: 2012-11-30T01:25:32Z
• Authors: Matthew S. Davenport; Benjamin L. Vigli...; Mahmoud M. Al-Hawary; Elaine M. Caoili; Ravi K. Kaza; Peter S. C. Liu; Katherine E. Maturen; Thomas L. Chenevert; Hero K. Hussain
• Keywords: Adult; Aged, 80 and over; Gadolinium DTPA; Male; Chi-Square Distribution; Liver Diseases; Contrast Media; Middle Aged; Magnetic Resonance Imaging; 3. Good health; 03 medical and health sciences; Dyspnea; 0302 clinical medicine; Image Interpretation, Computer-Assisted; Injections, Intravenous; Humans; Female; Prospective Studies; Artifacts; Aged

To determine whether acute transient dyspnea and/or arterial phase image degradation occurs more or less often after intravenous administration of gadoxetate disodium than with intravenous administration of gadobenate dimeglumine.Institutional review board approval and patient consent were obtained for this prospective observational study. One hundred ninety-eight gadolinium-based contrast media administrations (99 with gadoxetate disodium [10 mL, n = 97; 8 mL, n = 1; 16 mL, n = 1] and 99 with gadobenate dimeglumine [0.1 mmol per kilogram of body weight, maximum dose, 20 mL]) for hepatobiliary indications were assessed in 192 patients. Subjective patient complaints were assessed. Objective respiratory motion degradation on T1-weighted precontrast and dynamic postcontrast (arterial, venous, or late dynamic or extracellular) magnetic resonance (MR) imaging datasets were independently assessed in a randomized, blinded fashion by five readers using a five-point scale, with mean scores of 4 or greater indicating severe motion. Comparisons between agents were made by using χ(2) or Fisher exact test, where appropriate.Significantly more patient complaints of acute transient dyspnea occurred after gadoxetate disodium administration than gadobenate dimeglumine (14% [14 of 99] vs 5% [five of 99], P = .05). There were significantly more severely degraded arterial phase data sets for gadoxetate disodium than for gadobenate dimeglumine for both the general population (17% [17 of 99] vs 2% [two of 99], P = .0007) and the subpopulation with cirrhosis (19% [14 of 72] vs 3% [one of 37], P = .02). This effect did not extend to venous (1% [one of 99] vs 2% [two of 99], P > .99 [overall population]) or late dynamic or extracellular (2% [two of 99] vs 0% [zero of 99], P = .5 [overall population]) phases. No patient required treatment for self-limited dyspnea.Intravenous gadoxetate disodium can result in acute self-limiting dyspnea that can have a deleterious effect on arterial phase MR image quality and occurs significantly more often than with intravenous gadobenate dimeglumine.